The First Type III Domain of Fibronectin is Associated with the Expression of Cytokines within the Lung Tumor Microenvironment by Zheng, Mingzhe et al.
Journal of Cancer 2011, 2 
 
 
http://www.jcancer.org 
478 
J Jo ou ur rn na al l   o of f   C Ca an nc ce er r   
2011; 2: 478-483 
Short Research Communication 
The First Type III Domain of Fibronectin is Associated with the Expression 
of Cytokines within the Lung Tumor Microenvironment 
Mingzhe Zheng1, David M. Jones2, Carol Horzempa1, Aparna Prasad1, and Paula J. McKeown-Longo1  
1.  Center for Cell Biology and Cancer Research, Albany Medical College, Albany, New York, USA 
2.  Department of Pathology, Albany Medical College, Albany, New York, USA  
 Corresponding author: Paula J. McKeown-Longo, Ph.D., Center for Cell Biology and Cancer Research, Mail Code 165, Albany Medical 
College, 47 New Scotland Avenue, Albany, NY 12208. Telephone: (518) 265-5651; Fax: (518) 262-5669; E-mail: mckeowp@mail.amc.edu 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.08.04; Accepted: 2011.09.23; Published: 2011.09.27 
Abstract 
Recent studies have pointed to changes in tissue mechanics as a contributory element to the 
development of malignancies. Increased tissue rigidity is associated with the unfolding of the 
Type III domains of fibronectin within the extracellular matrix. The consequences of this 
unfolding on cellular functions within the lung are not well understood. In the present study, 
we evaluated the effect of a peptide representing a partially unfolded intermediate of the first 
Type III repeat of fibronectin (FnIII-1c) on inflammatory gene expression in adult human lung 
fibroblast cells. FnIII-1c induced expression of cytokines, CXCL1-3, IL-8 and TNF-, by lung 
fibroblast cells. The increase in IL-8 expression was dependent on Toll-like receptor 2 and 
NFB. Immunohistochemistry of tissue arrays representing squamous cell carcinoma of the 
lung revealed extensive stromal staining for IL-8 and fibronectin fibrils which were co-aligned 
with myofibroblasts. These data suggest a model in which unfolding of FnIII domains secondary 
to myofibroblast-generated tension may induce the release of cytokines by stromal fibroblasts 
present within the lung tumor. 
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INTRODUCTION 
Lung  cancer  is  the  leading  cause  of  can-
cer-related death with a world-wide annual death rate 
of 1.3 million people (1). In spite of developments in 
surgical techniques, chemotherapy and radiation on-
cology, the overall 5 year survival rate (15%) has re-
mained unchanged for decades. Inflammation medi-
ated destruction of the extracellular matrix, such as 
that which occurs in chronic obstructive pulmonary 
disease (COPD), asthma, tuberculosis and emphyse-
ma, is associated with increased risk of lung cancer 
(2-4).  The  association  between  lung  inflammatory 
disease and lung cancer has been recognized for sev-
eral  decades,  however,  the  mechanisms  underlying 
their linkage are not understood. Recent studies have 
suggested that chronic inflammation and extracellular 
matrix  remodeling  may  provide  a  mechanistic  link 
between COPD and the development of lung cancer 
(2).  
 Increased deposition of plasma fibronectin into 
the  lung  extracellular  matrix  is  seen  in  lung  cancer 
and has been implicated in promoting tumor cell pro-
liferation,  invasion  and  resistance  to  chemotherapy 
(5-10). Changes in the mechanical properties of lung 
tissue are seen in a number of disease states including 
cancer,  COPD,  asthma  and  emphysema,  where 
changes in the remodeling and stiffening of the ex-
tracellular matrix accompany disease progression. A 
recent  study  of  lung  fibrosis  in  bleomycin  treated 
mice, has shown that early fibrotic lesions in the lung 
are associated with large (as much as 30 fold) changes 
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in the lung tissue stiffness. These large increases in 
tissue rigidity occur in focal areas in association with 
extracellular  matrix  remodeling  and  infiltration  of 
myofibroblasts (11). The role of tissue stiffening in the 
initiation and progression of lung cancer has not been 
studied,  but  studies  on  breast  cancer  show  that  in-
creased tissue stiffening is positively correlated with 
disease progression (12). 
 The secondary structure of the fibronectin mol-
ecule is organized into individually folded domains 
termed Types I, II and III. The Type III domains are 
folded  into  structurally  stable  beta-pleated  sheets 
which  unfold  and  refold  in  response  to  changes  in 
intracellular tension. The biological role of many of 
these domains is not well understood, but accumu-
lating  evidence  has  indicated  that  the  Type  III  do-
mains of fibronectin present within the matrix become 
unfolded as the matrix becomes more rigid (13).  
 Steered  molecular  dynamics  has  been  used  to 
predict stable intermediate structures of partially un-
folded fibronectin Type III domains. One such inter-
mediate is recapitulated in a peptide comprised of the 
C-terminal  two-thirds  of  the  first  FnIII  domain, 
FnIII-1c (14). In the present study, we show that addi-
tion of FnIII-1c to adult lung fibroblasts causes a large 
increase in the expression of inflammatory cytokines 
including  CXCL1-3  and  IL-8.  Staining  of  tissue  mi-
croarrays  of  squamous  cell  carcinoma  shows  exten-
sive myofibroblast infiltration into a fibronectin rich 
stroma coupled with increased expression of IL-8. Our 
studies are consistent with a model in which myofi-
broblast driven unfolding of the secondary structure 
of  matrix  fibronectin  plays  a  role  in  the  initiation 
and/or maintenance of chronic inflammation within 
the tumor microenvironment.  
MATERIALS AND METHODS 
Analysis of gene expression  
 Primary  human  adult  lung  fibroblasts  were 
grown  in  lung/cardiac  fibroblast  growth  medium 
(Cell Applications, Inc. San Diego, CA) and used from 
passage  3-6.  In  most  experiments,  cell  monolayers 
were  serum-starved  overnight  with  serum-free  me-
dium  (lung/cardiac  fibroblast  basal  medium  con-
taining  0.1%  BSA)  before  treatment.  Recombinant 
His-tagged  fibronectin  modules,  III-1c  and  III-13, 
were prepared as described previously (15). Levels of 
contaminating endotoxin (<0.25 units/nmole of pro-
tein) in recombinant proteins were determined using 
the limulus amebocyte lysate assay, QCL-1000 (Lonza, 
Walkersville,  MD).  Total  RNA  was  isolated  using 
RNAeasy Plus Mini Kit (Qiagen, Valencia, CA). The 
RT2 First Strand Kit was used to convert RNA into 
first  strand  cDNA.  Mixtures  of  cDNA  and  SYBR® 
Green qPCR Mastermix were applied to the Human 
Inflammatory Response and Autoimmunity PCR Ar-
ray  Plates  (SABiosciences,  Frederick,  MD).  A  MyiQ 
cycler  system  (Bio-Rad  Laboratories)  was  used  for 
real-time PCR detection. The data were analyzed us-
ing the Excel-based PCR array data analysis templates 
provided by the manufacturer. The inhibitors of NFB 
signaling PS-1145 (Sigma-Aldrich) and BAY 11-7082 
(Calbiochem) were dissolved in DMSO. IL-8 protein 
concentration  was  measured  by  ELISA  (ELISA  Set 
from BD Biosciences, San Diego, CA). Blocking anti-
bodies  to  human  TLR2  and  TLR4  were  from  R&D 
Systems (Minneapolis, MN). 
Tissue section staining 
 Non-small  cell  human  lung  carcinoma  tissue 
with self-matching normal adjacent tissue microarray 
panels  (US  Biomax  Inc,  Rockville,  MD),  were  pro-
cessed  for  immuno-staining  using  peroxidase-based 
ABC system (Vector Laboratories, Burlingame, CA). 
The  primary  antibodies  and  their  dilution  were:  10 
g/ml IgG of anti-human FnIII-1 mouse monoclonal 
antibody  9D2,  25  g/ml  IgG  of  anti-human  IL-8 
mouse  monoclonal  antibody  (R&D  System,  Minne-
apolis,  MN  )  or  1:1600  dilution  ascites  of  anti-α 
smooth  muscle  actin  mouse  monoclonal  antibody 
(A2547, Sigma, St. Louis, MO). Color was developed 
by  reaction  with  3,3'-Diaminobenzidine.  Tissue  sec-
tions were counterstained with hematoxylin. 
RESULTS 
FnIII-1c induces the expression of inflamma-
tory cytokines in adult lung fibroblasts 
 To determine the effect of FnIII domain unfold-
ing on gene expression, we incubated human adult 
lung  fibroblast  cells  with  the  FnIII-1c  peptide.  This 
peptide recapitulates a stable intermediate structure 
which is formed when fibronectin undergoes unfold-
ing in response to cellular force (14). After 2 hours of 
incubation  with  FnIII-1c,  RNA  was  extracted  from 
cells and gene expression was analyzed by microar-
ray. As shown in Fig. 1A, several genes were upreg-
ulated in response to FnIII-1c and the five most highly 
upregulated genes (CXCL-1,2,3, IL-8 and TNF-) are 
shown in Fig. 1B. IL-8, which exhibited over a 100 fold 
increase  in  expression  in  response  to  FnIII-1c  was 
chosen  for  further  characterization.  The  microarray 
results  for  IL-8  were  confirmed  by  ELISA,  which 
demonstrated  a  dose-dependent  increase  in  the 
amount  of  IL-8  protein  present  in  the  conditioned 
medium of lung fibroblasts treated with FnIII-1c. The  Journal of Cancer 2011, 2 
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FnIII-13 domain served as control and had no effect 
on IL-8 expression (Fig. 1C). 
FnIII-1 induction of IL-8 requires TLR-2 and 
NFB 
 Expression  of  inflammatory  cytokines  is  often 
under  the  control  of  the  transcription  factor,  NFB, 
which is translocated to the nucleus following activa-
tion. To determine whether FnIII-1c activated NFB, 
nuclear lysates were prepared from lung fibroblasts 
treated with increasing doses of FnIII-1c. Western blot 
analysis of lysates  indicated that within an hour  of 
FnIII-1c  treatment,  there  was  a  dose  dependent  in-
crease in the accumulation of the p65/relA subunit of 
NFB  in  the  nucleus  (Fig.  2A).  To  verify  a  role  for 
NFkB in the induction of IL-8, cells were pretreated 
with  two  different  inhibitors  of  NFB  activation, 
PS-1178  and  BAY11-7072.  Incubation  of  cells  with 
FnIII-1c resulted in a large increase in the amount of 
IL-8 present in the conditioned medium when com-
pared with the control, FnIII-13 (Fig. 2B). In the pres-
ence of either inhibitor, FnIII-1c induction of IL-8 was 
decreased by 85%, confirming a role for NFkB in the 
induction of IL-8 by FnIII-1c. Activation of NFB can 
be  regulated  by  the  Toll-like  family  of  receptors 
(TLRs), transmembrane receptors which regulate the 
innate immune system. To evaluate a role for TLRs in 
the  induction  of  IL-8,  cells  were  incubated  with 
FnIII-1c in the presence of blocking antibody to either 
TLR2 or TLR4. Blocking antibody to TLR2 inhibited 
IL-8 expression in response to FnIII-1c (Fig. 2C). Nei-
ther control antibodies nor blocking antibody to TLR4 
inhibited IL-8 secretion in response to FnIII-1c. Taken 
together,  these  experiments  indicate  that  the  induc-
tion of IL-8 expression in lung fibroblasts by FnIII-1c 
occurs  through  the  TLR2  dependent  activation  of 
NFB. 
Fibronectin is preferentially expressed in the 
stroma of human squamous cell carcinoma  
Tissue  microarrays  containing  samples  of 
squamous cell carcinoma of the lung were stained for 
fibronectin  using  the  9D2  monoclonal  antibody  to 
fibronectin  which  recognizes  an  epitope  within  the 
FnIII-1 domain (16). Fig. 3A shows heavy staining for 
fibronectin in two samples of squamous cell carcino-
ma (panels a and b) in the stroma (stroma) adjacent to 
the infiltrating border of carcinoma cells (tumor). The 
stroma  show  extensive  fibrillar  staining  for  fibron-
ectin with aligned fibroblasts (F) and infiltrating in-
flammatory cells(I). There was also light to moderate 
diffuse  staining  for  fibronectin  within  the  tumor. 
Staining for fibronectin in normal lung tissue was less 
pronounced (panel c).  
 
 
Figure 1. FnIII-1c induces expression of inflamma-
tory genes in lung fibroblasts. (A) Monolayers of adult 
lung human fibroblasts were treated with 10 M FnIII-1c or 
PBS in serum-free culture medium supplemented with 0.1% 
BSA for 2 hrs. Expression profiling of genes was performed 
using the Human Inflammatory Response PCR Array. Pink 
lines indicate a 5-fold change in baseline. Five inflammatory 
genes  (labeled)  were  highly  upregulated  in  response  to 
FnIII-1c. (B) The fold induction of inflammatory genes by 
FnIII-1c  is  shown.  Values  represent  the  average  fold  in-
crease over housekeeping genes from 3 separate experi-
ments. (C) Human adult lung fibroblasts were treated with 
increasing concentrations of FnIII-1c or FnIII-13 for 4 hrs. 
IL-8 concentration in the culture medium was determined 
by ELISA. Error bars represent mean  SD.   Journal of Cancer 2011, 2 
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Figure 2. FnIII-1c induces TLR2-dependent expres-
sion  of  IL-8  in  human  adult  lung  fibroblasts.  (A) 
Human adult lung fibroblasts were incubated with the in-
dicated concentrations of FnIII-1c with PBS for 1 hr. The 
nuclear fraction was isolated and analyzed by immunoblot-
ting for the presence of the NFB protein, p65/rel A. Nu-
clear lamin A/C served as a loading control. (B) Cell were 
pretreated for 2 hrs with inhibitors of NFB signaling, 10 
μM of BAY11-7082 or 10 μM of PS-1145. Cell then received 
10 μM FnIII-1c for FnIII-13 for an additional 4 hrs. Condi-
tioned  medium  from  cells  was  collected  and  IL-8  was 
measured  by  ELISA.  (C)  Cells  were  pretreated  with 
blocking antibodies to human TLR2, TLR4, or control IgG 
for 1 hr prior to the addition of 10 μM FnIII-1c for 4 hrs. IL-8 
present in the conditioned medium was analyzed by ELISA. 
Positive  control  was  set  as  100%.  Error  bars  represent 
mean ± SD. 
 
The stroma of human lung tumors is enriched 
for myofibroblasts and IL-8 
 Figure 3B shows sequential sections of a squa-
mous  cell  carcinoma  of  the  lung  which  have  been 
stained for either smooth muscle cell actin (panel a) or 
IL-8  (panel  b).  The  tumor  stroma  (stroma)  stained 
heavily for smooth muscle actin and the staining pat-
tern  appeared  fibrillar,  similar  to  that  seen  with  fi-
bronectin  (Fig.  3A),  indicating  that  the  fibroblasts 
aligned  along  the  fibronectin  fibrils  are  myofibro-
blasts. IL-8 staining was present in both the stroma 
and  the  carcinoma  regions  of  the  tumor  (panel  b). 
Control staining was negative (panel c). These data 
indicate  that  in  squamous  cell  carcinoma  both  fi-
bronectin and IL-8 are heavily expressed in the tumor 
stroma and that the increased fibronectin within the 
tumor stroma is associated with an influx of myofi-
broblasts which are aligned along fibronectin fibers. 
These data are consistent with a model in which my-
ofibroblast contractility dependent remodeling of fi-
bronectin matrix initiates the release of inflammatory 
cytokines within the lung tumor microenvironment. 
DISCUSSION 
 Chronic  inflammation  and  fibrotic  disease  are 
believed to be contributing factors in the progression 
of lung cancer in high-risk patients (2,3). Our data are 
consistent with a model in which changes in the sec-
ondary structure of matrix fibronectin driven by in-
creased rigidity of lung tissue is part of a feed forward 
mechanism  controlling  the  release  of  inflammatory 
mediators into the lung microenvironment. The cyto-
kines released in response to FnIII-1c, IL-8, CXCL1, 2, 
and  3,  are  CXCR2  ligands  which  promote  both  in-
flammation and angiogenesis through the recruitment 
of  inflammatory  cells  and  the  mobilization  of  bone 
marrow  endothelial  cells  (17,18).  Our  data  suggest 
that  unfolding  of  the  FnIII-1  domain  within  fibron-
ectin  present  in  the  tumor  stroma  promotes  tumor 
progression  through  the  release  of  cytokines  from 
resident lung fibroblasts. 
The  FnIII-1c  peptide  used  in  this  study  was 
originally  called  anastellin  and  shown  to  have  an-
ti-angiogenic  and  anti-tumor  properties  (19).  We 
subsequently  showed  that  FnIII-1c  had  inhibitory 
effects on signaling pathways regulating endothelial 
microvessel  cell  proliferation  (20,21).  In  contrast, 
when  incubated  with  fibroblast  cells,  FnIII-1c  had 
little effect on growth and instead activated signaling 
pathways leading to the release of cytokines, which 
are  known  to  be  proangiogenic  (20,22).  These  data 
suggest  that  the  FnIII-1  domain  of  fibronectin  may 
have both pro- and anti-angiogenic roles within the 
tumor microenvironment.   Journal of Cancer 2011, 2 
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Figure 3. The stroma of squamous cell carcinoma is enriched in fibronectin. (A) Tissue sections from two lung 
squamous cell carcinomas (panels a and b) and a section of normal lung tissue (panel c) were stained for fibronectin . Fi-
broblasts (F) and Immune cells (I) are present. (B) Sequential sections of squamous cell carcinoma were stained for IL-8 
(panel a) and smooth muscle actin (SMA) (panel b). Control tissue stained with only secondary antibody (panel c). 
 
 
 Although the function of TLRs in the regulation 
of  inflammation  in  response  to  bacterial  pathogens 
has  been  recognized  for  many  years,  more  recent 
studies have pointed to a role of TLRs in mediating 
non-septic inflammatory responses. It is now becom-
ing clear that TLRs may play a role in the initiation 
and/or maintenance of inflammatory processes dur-
ing organ dysfunction and tissue injury, thereby con-
tributing to chronic illness. Both TLR2 and TLR4 are 
expressed in resident lung cells and both TLR2 and 
TLR4  have  been  reported  to  be  activated  through 
endogenous molecules including fragments of matrix 
proteins, such as hyaluronic acid (HA), the EDA do-
main  of  fibronectin  (FnEDA)  as  well  as  heat  shock 
proteins  and  -amyloid  (23,24).  Accumulating  evi-
dence  indicates  that  TLR  signaling  is  exceedingly 
complex  and  the  elicited  immune  response  is  both 
ligand- and cell-type specific (25). 
 We have shown in a previous study, that addi-
tion of Fn III-1c to human dermal fibroblasts results in 
the NFkB dependent release of inflammatory media-
tors, including IL-8 (22). In dermal fibroblasts, induc-
tion of cytokine expression was dependent on TLR4 
rather than TLR2. The basis for  the  involvement  of 
distinct  TLR  receptors  in  the  two  cell  types  is  not 
known. The ability of FnIII-1c to signal through either 
TLR2 or TLR4 suggests that FNnIII-1c does not bind 
directly to TLRs to initiate signaling, but instead in-
teracts with TLR signaling complexes by means of a 
co-receptor or ancillary binding protein.  
 The assembly of TLR containing signaling com-
plexes  which  differentially  function  to  regulate  Journal of Cancer 2011, 2 
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unique patterns of cytokine expression suggests that it 
may  be  possible  to  selectively  target  arms  of  TLR 
signaling pathways to treat disease without sacrific-
ing  pathways  controlling  host-defense.  Our  data 
suggest  that  force-dependent  remodeling  of  the  fi-
bronectin  matrix  promotes  inflammation  with  the 
lung. The identification of mechanically sensitive re-
sponse  elements  within  the  fibronectin  matrix,  and 
their  associated  signaling  pathways  will  provide 
novel  targets  for  the  treatment  of  chronic  lung  in-
flammation and may also represent a unique oppor-
tunity for developing therapies directed at early stage 
intervention in that population (i.e., former smokers, 
patients with COPD) who are at high risk for the de-
velopment of lung cancer.  
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